All Oncology News

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

Paul A. DiSilvestro, MD, discussed the pivotal SOLO-1 trial of maintenance olaparib in patients with BRCA-mutated ovarian cancer, updated survival data with the agent in this population, and the next steps for future research.

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

Lucio Gordan, MD, chief medical officer of Therapeutics & Analytics for Florida Cancer Specialists & Research Institute, is a featured speaker at the Illumina Genomics Forum in San Diego.

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

Richard M. Stone, MD, highlights how uproleselan disrupts E-selectin in the AML tumor microenvironment, the variety of AML regimens that uproleselan may amplify in efficacy, including chemotherapies and venetoclax combinations, and the need for further research to determine whether minimal residual disease negativity rates will improve patient prognoses.

Adjuvant treatment with nivolumab resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival over placebo in patients with completely resected stage IIB or IIC melanoma.

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

The addition of palbociclib to adjuvant endocrine therapy (ET) failed to improve invasive disease-free survival over ET alone in patients with estrogen receptor–positive, HER2-negative early breast cancer.

The FDA has granted a fast track designation to TTI-101 for the treatment of patients with relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma.

Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.

Rogaratinib induced an objective response rate similar to that of chemotherapy in patients with FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma who have received at least 1 prior platinum-containing chemotherapy.

Fox Chase Cancer Center is pleased to announce the hiring of Charnita Zeigler-Johnson, PhD, MPH, as Associate Director of Community Outreach and Engagement.

Salarius Pharmaceuticals has voluntarily paused enrollment of new patients into a phase 1/2 trial investigating seclidemstat in patients with Ewing sarcoma, sarcomas with FET-family translocations, and myxoid liposarcoma due to the death of a patient.

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

Ubamatamab monotherapy produced early clinical activity and an acceptable risk/benefit profile in heavily pretreated patients with ovarian cancer.

Sophia George, PhD, is hoping to find new strategies for early detection of ovarian cancer, a disease that is particularly deadly for African American, Caribbean, and Jewish women.

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

The FDA has granted an orphan drug designation to PCLX-001 for the treatment of patients with acute myeloid leukemia.

The FDA has granted an orphan drug designation to ET140203 for the treatment of patients with hepatoblastoma.

Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.

Pembrolizumab, alone and in combination with chemotherapy, maintained an overall survival benefit compared with cetuximab plus chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma at 4 years.

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

Investigators from Rutgers Cancer Institute of New Jersey examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival.